Previous studies have also shown that XRCC2 is abnormally expressed in a variety of tumors, including rectal and breast cancers, and that it participates in many cell signaling pathways (Chen 2018; Andreassen and Hanenberg 2019; Xu 2014; Bashir et al. 2014). This evidence concerns the gene XRCC2 and breast cancer.